A Comparison Laparoscopic With Open Gastric Cancer Surgery for Locally Advanced Gastric Cancer
Launched by MOSCOW CLINICAL SCIENTIFIC CENTER · Apr 19, 2016
Trial Information
Current as of May 21, 2025
Unknown status
Keywords
ClinConnect Summary
No description provided
Gender
ALL
Eligibility criteria
- Inclusion Criteria:
- • ECOG 0-1
- • ASA I-III
- • Histologically proven cancer of the stomach cT 2-4a(clinical stage tumor), N0-3, M0 at preoperative evaluation according to the American Joint Committee on Cancer (AJCC) Cancer Staging Manual Seventh Edition
- • Preoperative examination with no distant metastasis, no significantly enlarged lymph nodes around abdominal main artery, and tumor not a direct violation of the pancreas, spleen and other surrounding organs
- • The gastric tumors are located in the stomach, are macroscopically resectable by subtotal or total gastrectomy with D2 lymph node dissection.
- • Written informed consent
- Exclusion Criteria:
- • Clinically apparent distant metastasis
- • Free cancer cells
- • Bulky lymph node metastasis is detected by abdominal CT
- • Previous treatment with radiation therapy for any tumors.
- • Previous surgery for the present disease
- • Pregnancy
- • Psychiatric disease
About Moscow Clinical Scientific Center
The Moscow Clinical Scientific Center is a leading research institution dedicated to advancing medical science through innovative clinical trials and comprehensive patient care. With a focus on translational research, the center collaborates with healthcare professionals and academic institutions to develop cutting-edge therapies and improve treatment outcomes across various medical fields. By leveraging state-of-the-art technology and a multidisciplinary approach, the Moscow Clinical Scientific Center aims to enhance clinical practices and contribute to the global body of medical knowledge.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
Lipetsk, , Russian Federation
Moscow, , Russian Federation
Moscow, , Russian Federation
Moscow, , Russian Federation
Moscow, , Russian Federation
St. Petersburg, , Russian Federation
St.Petersburg, , Russian Federation
St.Petersburg, , Russian Federation
Kiev, , Ukraine
Patients applied
Trial Officials
Michail Byachov, MD, PhD
Study Chair
Moscow Clinical Scientific Center
Roman Izrailov, MD, PhD
Study Chair
Moscow Clinical Scientific Center
Boris Pomortsev, MD
Principal Investigator
Moscow Clinical Scientific Center
Pavel Kononets, MD, PhD
Principal Investigator
Moscow Oncological Hospital 62
Andrey Ryabov, MD, PhD
Principal Investigator
P.Herzen Moscow Oncological Research Institute
Vladimir Lyadov, MD, PhD
Principal Investigator
Treatment and Rehabilitation Centre of Health Ministry of Russia
Alexey Karachun, MD, PhD
Principal Investigator
N. Petrov National Research Institute of Oncology
Victor Kashchenko, MD, PhD
Principal Investigator
Federal Medical Biology Agence №122 the name of L.Sokolov
Andrey Pavlenko, MD, PhD
Principal Investigator
Leningradsky oncological center
Michail Lando, MD, PhD
Principal Investigator
Lipetsk regional oncological center
Sergey Baydo, MD, PhD
Principal Investigator
Lisod clinic Kiev
Igor Khatkov, MD, PhD
Study Director
Moscow Clinical Scientific Center
Michail Prostov
Principal Investigator
Moscow Clinical Scientific Center
Kirill Schostka, MD, PhD
Principal Investigator
Leningradsky oncological center
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported
Similar Trials